Generic selectors
Exact matches only
Search in title
Search in content
Post Type Selectors

ABUS – Arbutus Biopharma Corporation

Float Short %

7.45

Margin Of Safety %

Put/Call OI Ratio

0.32

EPS Next Q Diff

-0.02

EPS Last/This Y

0.12

EPS This/Next Y

0.03

Price

4.95

Target Price

5.67

Analyst Recom

1

Performance Q

12.5

Relative Volume

2.19

Beta

0.7

Ticker: ABUS




19 items of 1

DateSymbolLatestP/C OIP/C VolTotal OI
2025-11-17ABUS4.530.300.8548984
2025-11-18ABUS4.450.310.0149055
2025-11-19ABUS4.280.300.2050081
2025-11-20ABUS4.210.300.4850208
2025-11-21ABUS4.30.300.0150259
2025-11-24ABUS4.290.310.7246052
2025-11-25ABUS4.320.312.3146447
2025-11-26ABUS4.420.310.4346567
2025-12-01ABUS4.210.320.0047090
2025-12-02ABUS4.180.320.2247151
2025-12-03ABUS4.420.320.0947246
2025-12-04ABUS4.410.320.1847292
2025-12-05ABUS4.430.320.0347376
2025-12-08ABUS4.530.320.0247409
2025-12-09ABUS4.460.320.4947438
2025-12-10ABUS4.610.320.0047536
2025-12-11ABUS4.660.320.1447610
2025-12-12ABUS4.720.320.0147706
2025-12-15ABUS4.950.321.1447760
DateSymbolLatestP/C OIP/C VolTotal OI
19 items Current Page1 of 1




19 items of 1

DateTickerPriceCurrent Quarter Growth EstimateEBIT EstimationAverage EPS Estimate Current Year
2025-11-17ABUS4.5348.9- -0.26
2025-11-18ABUS4.4548.9- -0.26
2025-11-19ABUS4.2748.9- -0.26
2025-11-20ABUS4.2048.9- -0.26
2025-11-21ABUS4.3043.9- -0.26
2025-11-24ABUS4.2843.9- -0.26
2025-11-25ABUS4.3243.9- -0.26
2025-11-26ABUS4.4343.9- -0.26
2025-12-01ABUS4.2043.9- -0.26
2025-12-02ABUS4.1743.9- -0.26
2025-12-03ABUS4.4343.9- -0.26
2025-12-04ABUS4.4143.9- -0.26
2025-12-05ABUS4.4243.9- -0.26
2025-12-08ABUS4.5243.9- -0.26
2025-12-09ABUS4.4643.9- -0.26
2025-12-10ABUS4.6043.9- -0.26
2025-12-11ABUS4.6743.9- -0.26
2025-12-12ABUS4.7243.9- -0.26
2025-12-15ABUS4.9543.9- -0.26
DateTickerPriceCurrent Quarter Growth EstimateEBIT EstimationAverage EPS Estimate Current Year
19 items Current Page1 of 1




19 items of 1

DateTickerInsider TransactionsInstitutional TransactionsFloat Short
2025-11-17ABUS0.002.396.60
2025-11-18ABUS0.002.396.60
2025-11-19ABUS0.002.396.60
2025-11-20ABUS0.002.396.60
2025-11-21ABUS0.002.396.60
2025-11-24ABUS0.00-0.256.60
2025-11-25ABUS0.00-0.256.60
2025-11-26ABUS0.00-0.257.03
2025-12-01ABUS0.00-0.177.03
2025-12-02ABUS0.00-0.177.03
2025-12-03ABUS0.00-0.177.03
2025-12-04ABUS0.00-0.177.03
2025-12-05ABUS0.00-0.177.03
2025-12-08ABUS0.00-0.237.03
2025-12-09ABUS0.00-0.237.03
2025-12-10ABUS0.00-0.237.46
2025-12-11ABUS0.00-0.237.46
2025-12-12ABUS0.00-0.237.45
2025-12-15ABUS0.00-0.217.45
DateTickerInsider TransactionsInstitutional TransactionsFloat Short
19 items Current Page1 of 1

[stock_market_widget type="chart" template="candlestick" assets="ABUS" range="1y" interval="1d" price_field="close" heading="{symbol}" candle_border_width="1" candle_bullish_background_color="#21BA45" candle_bearish_background_color="#DB2828" candle_bullish_border_color="#21BA45" candle_bearish_border_color="#DB2828" axes_color="#000000" tooltip_text_color="#262626" tooltip_background_color="#ffffff" range_selector="true" volume_enabled="true" axes_enabled="true" tooltip_enabled="false" zoom_enabled="true" save_image_enabled="true" volume_bar_fill_color="#5679FF" api="yahoo-finance"]

Last Quarter Act. EPS

-0.04

Avg. EPS Est. Current Quarter

-0.06

Avg. EPS Est. Next Quarter

-0.06

Insider Transactions

Institutional Transactions

-0.21

Beta

0.7

Average Sales Estimate Current Quarter

Average Sales Estimate Next Quarter

Fair Value

Quality Score

26

Growth Score

33

Sentiment Score

70

Actual DrawDown %

23.8

Max Drawdown 5-Year %

-66

Target Price

5.67

P/E

Forward P/E

PEG

P/S

65.16

P/B

12.28

P/Free Cash Flow

EPS

-0.22

Average EPS Est. Cur. Y​

-0.26

EPS Next Y. (Est.)

-0.23

Target Price Estimates Raised

Target Price Estimates Lowered

Profit Margin

-289.45

Relative Volume

2.19

Return on Equity vs Sector %

-81.6

Return on Equity vs Industry %

-66.5

EPS 1 7Days Diff

EPS 1 30Days Diff

-0.01

EBIT Estimation

[stock_market_widget type=”table-options” template=”gradient” color=”#5679FF” assets=”ABUS” fields=”contract_symbol,type,strike,price,change_pct,implied_volatility,change_abs,open_interest,volume,in_the_money,bid,ask” pagination=”true” rows_per_page=”21″ sort_direction=”asc” alignment=”left” search=”true” sort_field=”strike” api=”yahoo-finance”]
[stock_market_widget type=”chart-options” template=”basic” color=”#5679FF” assets=”ABUS” options_type=”calls” x_axis_field=”strike” y_axis_field=”price” axes=”true” cursor=”true” display_currency_symbol=”true” api=”yf”]
[stock_market_widget type=”chart-options” template=”basic” color=”#5679FF” assets=”ABUS” options_type=”puts” x_axis_field=”strike” y_axis_field=”price” axes=”true” cursor=”true” display_currency_symbol=”true” api=”yf”]
[stock_market_widget type=”chart-options” template=”basic” color=”#5679FF” assets=”ABUS” options_type=”calls” x_axis_field=”strike” y_axis_field=”implied_volatility” axes=”true” cursor=”true” display_currency_symbol=”true” api=”yf”]
[stock_market_widget type=”chart-options” template=”basic” color=”#5679FF” assets=”ABUS” options_type=”puts” x_axis_field=”strike” y_axis_field=”implied_volatility” axes=”true” cursor=”true” display_currency_symbol=”true” api=”yf”]
[stock_market_widget type=”chart-options” template=”basic” color=”#5679FF” assets=”ABUS” options_type=”calls” x_axis_field=”strike” y_axis_field=”volume” axes=”true” cursor=”true” display_currency_symbol=”true” api=”yf”]
[stock_market_widget type=”chart-options” template=”basic” color=”#5679FF” assets=”ABUS” options_type=”puts” x_axis_field=”strike” y_axis_field=”volume” axes=”true” cursor=”true” display_currency_symbol=”true” api=”yf”]
Arbutus Biopharma Corporation
Sector: Healthcare
Industry: Biotechnology
Employees: 44
Arbutus Biopharma Corporation, a clinical-stage biopharmaceutical company, develops novel therapeutics for infectious disease in the United States. Its chronic Hepatitis B virus product pipeline comprises Imdusiran, conjugated GalNAc, subcutaneously-delivered RNAi therapeutic product candidate which is in phase 1 and phase 2a clinical trials that suppresses all HBV antigens, including HBsAg expression; and AB-101, an oral PD-L1 inhibitor, which is in phase 1a/1b clinical trial that has the potential to reawaken patients' HBV-specific immune response by inhibiting PD-L1. The company has licensing agreement with Alnylam Pharmaceuticals, Inc. to develop and commercialize products with LNP delivery technology. The company was formerly known as Tekmira Pharmaceuticals Corporation and changed its name to Arbutus Biopharma Corporation in July 2015. Arbutus Biopharma Corporation was incorporated in 2005 is headquartered in Warminster, Pennsylvania.
stock quote shares ABUS – Arbutus Biopharma Corporation Stock Price stock today
news today ABUS – Arbutus Biopharma Corporation stock forecast ,stock prediction 2023 2024 2025
marketwatch ABUS – Arbutus Biopharma Corporation yahoo finance google finance
stock history ABUS – Arbutus Biopharma Corporation invest stock market
stock prices ABUS premarket after hours
ticker ABUS fair value insiders trading

ABUS – Arbutus Biopharma Corporation

Float Short %

7.45

Margin Of Safety %

Put/Call OI Ratio

0.32

EPS Next Q Diff

-0.02

EPS Last/This Y

0.12

EPS This/Next Y

0.03

Price

4.95

Target Price

5.67

Analyst Recom

1

Performance Q

12.5

Relative Volume

2.19

Beta

0.7

Ticker: ABUS




19 items of 1

DateSymbolLatestP/C OIP/C VolTotal OI
2025-11-17ABUS4.530.300.8548984
2025-11-18ABUS4.450.310.0149055
2025-11-19ABUS4.280.300.2050081
2025-11-20ABUS4.210.300.4850208
2025-11-21ABUS4.30.300.0150259
2025-11-24ABUS4.290.310.7246052
2025-11-25ABUS4.320.312.3146447
2025-11-26ABUS4.420.310.4346567
2025-12-01ABUS4.210.320.0047090
2025-12-02ABUS4.180.320.2247151
2025-12-03ABUS4.420.320.0947246
2025-12-04ABUS4.410.320.1847292
2025-12-05ABUS4.430.320.0347376
2025-12-08ABUS4.530.320.0247409
2025-12-09ABUS4.460.320.4947438
2025-12-10ABUS4.610.320.0047536
2025-12-11ABUS4.660.320.1447610
2025-12-12ABUS4.720.320.0147706
2025-12-15ABUS4.950.321.1447760
DateSymbolLatestP/C OIP/C VolTotal OI
19 items Current Page1 of 1




19 items of 1

DateTickerPriceCurrent Quarter Growth EstimateEBIT EstimationAverage EPS Estimate Current Year
2025-11-17ABUS4.5348.9- -0.26
2025-11-18ABUS4.4548.9- -0.26
2025-11-19ABUS4.2748.9- -0.26
2025-11-20ABUS4.2048.9- -0.26
2025-11-21ABUS4.3043.9- -0.26
2025-11-24ABUS4.2843.9- -0.26
2025-11-25ABUS4.3243.9- -0.26
2025-11-26ABUS4.4343.9- -0.26
2025-12-01ABUS4.2043.9- -0.26
2025-12-02ABUS4.1743.9- -0.26
2025-12-03ABUS4.4343.9- -0.26
2025-12-04ABUS4.4143.9- -0.26
2025-12-05ABUS4.4243.9- -0.26
2025-12-08ABUS4.5243.9- -0.26
2025-12-09ABUS4.4643.9- -0.26
2025-12-10ABUS4.6043.9- -0.26
2025-12-11ABUS4.6743.9- -0.26
2025-12-12ABUS4.7243.9- -0.26
2025-12-15ABUS4.9543.9- -0.26
DateTickerPriceCurrent Quarter Growth EstimateEBIT EstimationAverage EPS Estimate Current Year
19 items Current Page1 of 1




19 items of 1

DateTickerInsider TransactionsInstitutional TransactionsFloat Short
2025-11-17ABUS0.002.396.60
2025-11-18ABUS0.002.396.60
2025-11-19ABUS0.002.396.60
2025-11-20ABUS0.002.396.60
2025-11-21ABUS0.002.396.60
2025-11-24ABUS0.00-0.256.60
2025-11-25ABUS0.00-0.256.60
2025-11-26ABUS0.00-0.257.03
2025-12-01ABUS0.00-0.177.03
2025-12-02ABUS0.00-0.177.03
2025-12-03ABUS0.00-0.177.03
2025-12-04ABUS0.00-0.177.03
2025-12-05ABUS0.00-0.177.03
2025-12-08ABUS0.00-0.237.03
2025-12-09ABUS0.00-0.237.03
2025-12-10ABUS0.00-0.237.46
2025-12-11ABUS0.00-0.237.46
2025-12-12ABUS0.00-0.237.45
2025-12-15ABUS0.00-0.217.45
DateTickerInsider TransactionsInstitutional TransactionsFloat Short
19 items Current Page1 of 1

[stock_market_widget type="chart" template="candlestick" assets="ABUS" range="1y" interval="1d" price_field="close" heading="{symbol}" candle_border_width="1" candle_bullish_background_color="#21BA45" candle_bearish_background_color="#DB2828" candle_bullish_border_color="#21BA45" candle_bearish_border_color="#DB2828" axes_color="#000000" tooltip_text_color="#262626" tooltip_background_color="#ffffff" range_selector="true" volume_enabled="true" axes_enabled="true" tooltip_enabled="false" zoom_enabled="true" save_image_enabled="true" volume_bar_fill_color="#5679FF" api="yahoo-finance"]

Last Quarter Act. EPS

-0.04

Avg. EPS Est. Current Quarter

-0.06

Avg. EPS Est. Next Quarter

-0.06

Insider Transactions

Institutional Transactions

-0.21

Beta

0.7

Average Sales Estimate Current Quarter

Average Sales Estimate Next Quarter

Fair Value

Quality Score

26

Growth Score

33

Sentiment Score

70

Actual DrawDown %

23.8

Max Drawdown 5-Year %

-66

Target Price

5.67

P/E

Forward P/E

PEG

P/S

65.16

P/B

12.28

P/Free Cash Flow

EPS

-0.22

Average EPS Est. Cur. Y​

-0.26

EPS Next Y. (Est.)

-0.23

Target Price Estimates Raised

Target Price Estimates Lowered

Profit Margin

-289.45

Relative Volume

2.19

Return on Equity vs Sector %

-81.6

Return on Equity vs Industry %

-66.5

EPS 1 7Days Diff

EPS 1 30Days Diff

-0.01

EBIT Estimation

[stock_market_widget type=”table-options” template=”gradient” color=”#5679FF” assets=”ABUS” fields=”contract_symbol,type,strike,price,change_pct,implied_volatility,change_abs,open_interest,volume,in_the_money,bid,ask” pagination=”true” rows_per_page=”21″ sort_direction=”asc” alignment=”left” search=”true” sort_field=”strike” api=”yahoo-finance”]
[stock_market_widget type=”chart-options” template=”basic” color=”#5679FF” assets=”ABUS” options_type=”calls” x_axis_field=”strike” y_axis_field=”price” axes=”true” cursor=”true” display_currency_symbol=”true” api=”yf”]
[stock_market_widget type=”chart-options” template=”basic” color=”#5679FF” assets=”ABUS” options_type=”puts” x_axis_field=”strike” y_axis_field=”price” axes=”true” cursor=”true” display_currency_symbol=”true” api=”yf”]
[stock_market_widget type=”chart-options” template=”basic” color=”#5679FF” assets=”ABUS” options_type=”calls” x_axis_field=”strike” y_axis_field=”implied_volatility” axes=”true” cursor=”true” display_currency_symbol=”true” api=”yf”]
[stock_market_widget type=”chart-options” template=”basic” color=”#5679FF” assets=”ABUS” options_type=”puts” x_axis_field=”strike” y_axis_field=”implied_volatility” axes=”true” cursor=”true” display_currency_symbol=”true” api=”yf”]
[stock_market_widget type=”chart-options” template=”basic” color=”#5679FF” assets=”ABUS” options_type=”calls” x_axis_field=”strike” y_axis_field=”volume” axes=”true” cursor=”true” display_currency_symbol=”true” api=”yf”]
[stock_market_widget type=”chart-options” template=”basic” color=”#5679FF” assets=”ABUS” options_type=”puts” x_axis_field=”strike” y_axis_field=”volume” axes=”true” cursor=”true” display_currency_symbol=”true” api=”yf”]
Arbutus Biopharma Corporation
Sector: Healthcare
Industry: Biotechnology
Employees: 44
Arbutus Biopharma Corporation, a clinical-stage biopharmaceutical company, develops novel therapeutics for infectious disease in the United States. Its chronic Hepatitis B virus product pipeline comprises Imdusiran, conjugated GalNAc, subcutaneously-delivered RNAi therapeutic product candidate which is in phase 1 and phase 2a clinical trials that suppresses all HBV antigens, including HBsAg expression; and AB-101, an oral PD-L1 inhibitor, which is in phase 1a/1b clinical trial that has the potential to reawaken patients' HBV-specific immune response by inhibiting PD-L1. The company has licensing agreement with Alnylam Pharmaceuticals, Inc. to develop and commercialize products with LNP delivery technology. The company was formerly known as Tekmira Pharmaceuticals Corporation and changed its name to Arbutus Biopharma Corporation in July 2015. Arbutus Biopharma Corporation was incorporated in 2005 is headquartered in Warminster, Pennsylvania.
stock quote shares ABUS – Arbutus Biopharma Corporation Stock Price stock today
news today ABUS – Arbutus Biopharma Corporation stock forecast ,stock prediction 2023 2024 2025
marketwatch ABUS – Arbutus Biopharma Corporation yahoo finance google finance
stock history ABUS – Arbutus Biopharma Corporation invest stock market
stock prices ABUS premarket after hours
ticker ABUS fair value insiders trading